Abstract:Abstract Background Lung cancer is the leading cause of cancer-related death worldwide, among which lung adenocarcinoma (LUAD) is the most common type. Identified as a hallmark of cancer, the dysregulated cell cycle progression plays an important role in the promotion and progression of LUAD. This article aims to elucidate the heterogeneity between CDKN2A-CDK/cyclin-RB1 cell cycle progression pathway altered /non-altered patients with LUAD, thus helping us have a better understanding of the effect of the aberrant cell cycle. Material and Methods The data of this study were downloaded from The Cancer Genome Atlas (TCGA) data portal (https://portal.gdc.cancer.gov/) and UCSC Xena Browser (http://xena.ucsc.edu/), including simple nucleotide variation data, RNA-seq gene expression data, survival data, clinical data, and miRNA expression data. After matching the RNA-seq gene expression data, simple nucleotide variation data, miRNA expression data, and survival data with clinical data, 510 gene and long non-coding RNA expression data, 506 simple nucleotide variation data, 440 microRNA expression data, and 497 survival data were included in this study for further analysis. R software (version 4.0.3) was used for analysis. Results After dividing the patients into mutation (n = 57) and wild (n = 453) groups according to the cell cycle progression pathway status, we found no significant difference in survivorship between them. The mutation group had a higher mutational load and mutational rates of various genes such as tumor protein P53 (TP53) compared to the wild group. Subsequently, we analyzed the differentially expressed genes (DEGs) between the two groups. Among the 58387 genes analyzed, 302 were upregulated, and 354 were downregulated in the mutation group. Enrichment analysis indicated that these DEGs were closely related to metabolism items and cell cycle-related events. After performing immune cell infiltration analysis, we found the two groups have different patterns of immune cell profiling. Albeit the immune and stromal scores were higher in the wild group, we failed to find any significant difference between the two groups. Finally, we build a computational model to predict the cell cycle progression pathway-related gene mutation by LASSO-binary logistic regression analysis, the predictive accuracy of which is 0.88. Conclusion In summary, our study compared the genetic and microenvironment differences between cell cycle progression pathway altered /non-altered patients with LUAD by analyzing the data from TCGA datasets. We hope our findings could improve our understanding of the heterogeneity between the two kinds of patients, thus providing new insight into LUAD patients' treatments.

Genetic Analyses of Differences Between Solid and Nonsolid Predominant Lung Adenocarcinomas

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Genetic Characteristics of Lung Adenocarcinoma with Ground-Glass Opacity Component.

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Bioinformatics Analyses of the Differences Between Lung Adenocarcinoma and Squamous Cell Carcinoma Using the Cancer Genome Atlas Expression Data.

Genetic and Microenvironmental Differences in Non-Smoking Lung Adenocarcinoma Patients Compared with Smoking Patients

Disparate genomic characteristics of patients with early-stage lung adenocarcinoma manifesting as radiological subsolid or solid lesions

Differences of molecular events driving pathological and radiological progression of lung adenocarcinoma

Comprehensive analysis of lung adenocarcinoma: Unveiling differential gene expression, survival‐linked genes, subtype stratification, and immune landscape implications

Distinct gene mutation profiles among multiple and single primary lung adenocarcinoma

Single-cell RNA sequencing reveals distinct tumor microenvironment of ground glass nodules and solid nodules in lung adenocarcinoma

Genetic and tumor microenvironment differences between cell cycle progression pathway altered/non-altered patients with lung adenocarcinoma

Identification of molecular subtypes in lung adenocarcinoma based on DNA methylation and gene expression profiling—a bioinformatic analysis

Genomic And Tumor Microenvironment Differences Between Cell Cycle Progression Pathway Altered/Non-Altered Patients With Lung Adenocarcinoma

In-depth analysis of immune cell landscapes reveals differences between lung adenocarcinoma and lung squamous cell carcinoma

Lung adenocarcinoma: selection of surgical approaches in solid adenocarcinoma from the viewpoint of clinicopathologic features and tumor microenvironmental heterogeneity

Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features

Identification of Differentially Expressed Genes in Lung Adenocarcinoma Cells Using Single-Cell RNA Sequencing Not Detected Using Traditional RNA Sequencing and Microarray

Cell Trajectory-Related Genes of Lung Adenocarcinoma Predict Tumor Immune Microenvironment and Prognosis of Patients

The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma

Relationship Between PD-L1 Expression and Molecular Aberrances in Lung Adenocarcinoma with Solid Components